• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Trump ad­min­is­tra­tion opens the door to low­er drug prices as Medicare Ad­van­tage plans are pushed to step ther­a­py ...

7 years ago
Pharma

14-year-old par­tial hold comes back to haunt Gem­phire, bat­ter­ing shares and wreck­ing time­lines

7 years ago
R&D
Pharma

Min­ing re­al world da­ta for drug de­vel­op­ment in­sights, Wood­ford-backed AI firm seeks $77M Lon­don IPO

7 years ago
Financing

Al­ler­gan picks up op­tion for Ed­i­tas' rare eye dis­ease drug; Cure­Ge­net­ics bags $17M

7 years ago
News Briefing

PAH ther­a­py tanks in Phase III, oblit­er­at­ing Bellerophon's stock

7 years ago
R&D

New re­port sin­gles out Big Phar­ma play­ers for ring­ing their block­busters with patents while hik­ing prices for years

7 years ago
Pharma

GSK chief Em­ma Walm­s­ley rounds out her top team with CFO pick — but per­for­mance lags

7 years ago
People
Bioregnum

Spark takes a beat­ing as he­mo­phil­ia safe­ty set­backs tor­pe­do stock, bur­nish ri­val Bio­Marin

7 years ago
R&D

NEA, 5AM back a $50M play to steer gene ther­a­pies to the clin­ic at Ak­ou­os — the lat­est start­up in hear­ing

7 years ago
Financing
Startups

Boehringer or­ga­nizes a coali­tion in search of first CF gene ther­a­py, work­ing with re­search, man­u­fac­tur­ing part­ners

7 years ago
R&D
Pharma

Pro­tag­o­nist rais­es $22M to re­vive PTG-100; Paratek's an­tibi­ot­ic shows non-in­fe­ri­or­i­ty

7 years ago
News Briefing

What's big­ger than a uni­corn? Sa­mumed stuns yet again as an­ti-ag­ing pipeline draws $438M at $12B val­u­a­tion

7 years ago
Financing

Block­buster dreams quashed, Iron­wood drops As­traZeneca's $1.3B gout drug dis­as­ter

7 years ago
Pharma

Who are the most pro­duc­tive drug de­vel­op­ers in bio­phar­ma? Our top-20 list has lots of sur­pris­es

7 years ago
R&D
Special

No sur­prise: FDA hands Pain Ther­a­peu­tics an­oth­er slap­down on Re­moxy, forc­ing a quick re­struc­tur­ing

7 years ago
R&D

Ovid's snap­shot of broad ef­fi­ca­cy da­ta for their PhII An­gel­man syn­drome tri­al can't stop a rout -- shares crushed

7 years ago
R&D

With PD-1 OK loom­ing, Re­gen­eron antes $100M on blue­bird al­liance for next-gen TCR cell ther­a­py pact

7 years ago
Pharma

That big HKEX biotech boom is start­ing to look shaky; Al­ny­lam gets a green light in the UK for patisir­an

7 years ago
News Briefing

Cell Med­ica scoops Kite Phar­ma's Chris Now­ers as CEO; Shire vet jumps to Edi­Gene as CEO

7 years ago
Peer Review

Lil­ly Asian Ven­tures backs Im­pact's PARP re­search again, chip­ping in for $30M Se­ries C led by Decheng Cap­i­tal

7 years ago
Financing
China

Roche gets some reg­u­la­to­ry love for its break­through quest on a PhI­II Hunt­ing­ton's drug

7 years ago
Pharma

Tom Hugh­es jumps ship at Zaf­gen and gets back to the helm of a note­wor­thy biotech

7 years ago
People

No­var­tis on­col­o­gy vet Ste­fan Scher­er joins biotech mi­gra­tion to head clin­i­cal work, CAR-T part­ner­ship at Cel­lec­tis

7 years ago
People

Bris­tol-My­ers, Scripps re­search team touts a new way to con­trol 3D ar­chi­tec­ture of ge­net­ic drugs

7 years ago
Discovery
First page Previous page 1006100710081009101010111012 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.